Summary of clinical features in 11 deaths
| Characteristics | n (%) |
|---|---|
| Age >60 years | 1 (9.1%) |
| LDH >250 U/L | 8 (72.7%) |
| IPI ≥ 3 | 7 (63.6%) |
| Bone marrow involvement | 4 (36.4%) |
| Bowel involvement | 5 (45.5%) |
| EBER | |
| Negative | 4 (36.4%) |
| Unavailable data | 7 (63.6%) |
| Dose reduction during chemotherapy | 2 (18.2%) |
| Best tumor response in first line CODOX-M therapy | |
| Complete remission | 5 (45.5%) |
| Progressed disease | 6 (55.5%) |
| Cause of death | |
| Treatment related death | 2 (18.2%) |
| Died for progressed disease | 9 (81.8%) |
LDH, lactate dehydrogenase; IPI, international prognosis index; EBER, Epstein-Barr virus-encoded small nuclear early region; CODOX-M, cyclophosphamide, vincristine, doxorubicin, methotrexate.